Accessibility Menu
BioVaxys Technology logo

BioVaxys Technology(OTC) BVAXF

Market Cap$3.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-96%
5 Year-94%
1 Year-49%
1 Month+29%
$0.11
-0.18%
-0.00Today
BioVaxys Technology last closing stock price
MetricPriceDate
Last closeUSD 0.112026-07-29
BioVaxys Technology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.91%USD 0.112026-07-22
1 month+29.39%USD 0.092026-06-29
3 month+112.31%USD 0.052026-04-30
Year to date-33.79%USD 0.172025-12-31
1 year-48.58%USD 0.222025-07-29
3 year-33.86%USD 0.172023-07-28
5 year-93.94%USD 1.852021-07-30
Since inception-96.26%USD 3.002020-10-19

BioVaxys Technology Financials at a Glance

Market Cap

$3.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$6.04M

EPS (TTM)

-$0.16

P/E Ratio

-0.70

Dividend

$0.00

Beta (Volatility)

0.05 (Low)

Price

$0.11

Volume

21,045

Open

$0.08

Previous Close

$0.11

Daily Range

$0.08 - $0.11

52-Week Range

$0.02 - $0.27

Estimated Earnings Date

Mar 31, 2025

BVAXF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioVaxys Technology

BioVaxys Technology Corp. is a clinical-stage biotechnology company focused on developing innovative vaccine platforms for antiviral diseases and various cancers. The company is advancing several key candidates, including vaccines for SARS-CoV-2 and oncology treatments.

Products and Services
  • BVX-0320 and BVX-0121: SARS-CoV-2 vaccines targeting different variants
  • BVX-0918A and BVX-0918C: Tumor cell vaccines for ovarian and cervical cancers
  • CoviDTH: An immunodiagnostic tool for detecting immune responses to SARS-CoV-2
Growth Outlook
  • Strategic collaborations with WuXi Biologics and The Ohio State University enhance development capabilities
  • Focus on expanding vaccine pipeline to address emerging health threats
  • Potential market growth driven by increasing demand for innovative cancer therapies
Financial Highlights
  • Recent quarterly net income of -$910,056 reflects ongoing investment in R&D
  • Trailing twelve months (TTM) revenue remains at $0, indicating early-stage development
  • Cash and short-term investments totaled $4,080, supporting operational needs
BioVaxys Technology Corp. is positioned in the biotechnology sector, focusing on the development of vaccines that address significant health challenges. The company’s innovative approach to vaccine development, particularly in the context of COVID-19 and cancer, highlights its potential for growth. Strategic partnerships with established organizations bolster its research and development efforts, aiming to bring effective solutions to market. Despite current financial challenges, including a net income loss, the company’s commitment to advancing its product pipeline may attract interest from investors looking for opportunities in the biotechnology field.
AI Generated • Jul 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

James Christopher Passin

Website

www.biovaxys.com

Headquarters

Etobicoke, ON V6C 1L6, CA

BVAXF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

121.88%

Return on Capital

N/A

Return on Assets

-237.77%

Earnings Yield

-1.43%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

29.15M

Volume

21.05K

Avg. Volume

39.87K

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$4.85M

EBITDA

-CA$4.65M

Operating Cash Flow

-CA$2.97M

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$4.03M

Cash & ST Invst.

CA$4.08K

Total Debt

CA$133.72K

BioVaxys Technology Performance Analysis

BioVaxys Technology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-10-31CAD 0N/A
20222022-10-31CAD 0N/A
20232023-10-31CAD 0N/A
20242024-10-31CAD 0N/A
BioVaxys Technology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-10-31N/A
Q12025-01-31N/A
Q22025-04-30N/A
Q32025-07-31N/A
BioVaxys Technology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-10-31CAD -0.62N/A
20222022-10-31CAD -0.9349.9%
20232023-10-31CAD -0.42-54.2%
20242024-10-31CAD -0.15-65.1%
BioVaxys Technology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-10-31-131.5%
Q12025-01-3167.2%
Q22025-04-30-12.2%
Q32025-07-3132.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$3.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.09M

N/A

Employees

3

N/A

Net Income

-CA$910.06K

+23.3%

EBITDA

-CA$656.85K

+18.1%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

CA$4.08K

-99.2%

Total Debt

CA$133.72K

+64.7%

Accounts Receivable

CA$0.00

-100.0%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$133.72K

+64.7%

Return on Assets

-2.38%

N/A

Return on Invested Capital

92.14%

N/A

Free Cash Flow

-CA$1.06M

-156.3%

Operating Cash Flow

-CA$1.06M

-156.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KNBIFKane Biotech Inc.
$0.02+11.38%
BIXTBioxytran, Inc.
$0.02+7.14%
LOBEFLobe Sciences Ltd.
$0.01-14.29%
BZYRBurzynski Research Institute, Inc.
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About BVAXF

What is the current price of BioVaxys Technology?

BioVaxys Technology is trading at $0.11 per share.

What is the 52-week range for BioVaxys Technology?

Over the past 52 weeks, BioVaxys Technology has traded between $0.02 and $0.27.

How much debt does BioVaxys Technology have?

As of the most recent reporting period, BioVaxys Technology reported total debt of CA$96.72K.

How much cash does BioVaxys Technology have on hand?

BioVaxys Technology reported CA$2.95K in cash and cash equivalents in its most recent financial results.

What is BioVaxys Technology’s dividend yield?

BioVaxys Technology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services